longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Cardiff Oncology

CRDF

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -2.48, within the reasonable range, cheaper than 42.98% of the time in the past 5 years, and the industry ranks 286/602, the industry Median -2.32.

-2.48xP/E
$1.28Stock price
$-0.52Earnings per share
-2.48xP/E
Stock price$1.28Earnings per share$-0.52

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-2.68x
Typical range
-4.31x–-1.78x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-57.29x148.77%$185.61B
MRNAUSModerna
-24.68x15.47%$77.78B
CSLLYUSCSL Limited
-23.35x--$60.23B
NTRAUSNatera
-306.35x10.38%$58.92B
RVMDUSRevolution Medicines
-24.23x63.53%$42.84B
INSMUSInsmed
-30.33x74.62%$26.54B
ROIVUSRoivant Sciences
-98.02x146.49%$26.10B
BNTXUSBioNTech SE
-12.74x17.57%$24.93B
SMMTUSSummit Therapeutics
-15.26x20.08%$13.07B
BBIOUSBridgebio Pharma
-18.73x28.57%$12.96B
TWSTUSTwist Bioscience
-88.61x24.61%$12.12B
MDGLUSMadrigal Pharma
-36.47x51.07%$11.86B
KYMRUSKymera Therapeutics
-32.14x4.94%$9.63B
ARWRUSArrowHead Pharma
-29.17x36,308.30%$9.33B
IBRXUSImmunityBio
-9.23x152.63%$9.16B
CYTKUSCytokinetics
-10.21x6.37%$9.13B
PCVXUSVaxcyte
-7.96x48.80%$8.47B
ABVXUSAbivax SA
-17.76x20.94%$8.27B
PRAXUSPraxis Precision Medicines
-23.20x3.05%$7.87B
SYREUSSpyre Therapeutics
-51.12x47.81%$7.68B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.